Ifm Therapeutics Company Profile

Aggregated data from the web about Ifm Therapeutics

Company Name	Ifm Therapeutics
Website	https://www.ifmthera.com
Snippet	IFM Therapeutics's $27M Series A closed. 2017. SEPTEMBER. Preclinical PoC for both NLRP3 and STING agonists demonstrated. SEPTEMBER. $2.32B sale of IFM Uno to BMS closed; IFM Therapeutics, LLC created as a spin-out, and IFM Tre launched. 2018. FEBRUARY. BMS dosed initial patient with first-in-class NLRP3 agonist, IFM-1222 ...
Type	Private
Founded	2015
Website	ifmthera.com
Formerly	IFM (2016–2018)
Industry	Pharmaceutical
Key people	Gary Glick (CEO), Jean-Francoise Formela (Chairman)
Subsidiaries	IFM Due

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.